pharmaphorum2mon
FDA clears AZ's Imfinzi for aggressive lung cancer
AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.
National Institute for Health and Care Excellence26d
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy ... The list price is £2,466 per 500‑mg vial (excluding VAT; BNF online, accessed July 2024). The cost of a course of perioperative ...
pharmaphorum2d
FDA gives AZ the nod for Imfinzi in biliary tract cancer
The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...
Nasdaq7d
AstraZeneca: CHMP Recommends Approval Of Imfinzi In The EU
(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.